Study of MLN8237 in Combination With Irinotecan and Temozolomide

Trial ID or NCT#

NCT01601535,29,26500,45600

Status

not recruiting iconNOT RECRUITING

Purpose

The goal of the first part of this clinical trial (Phase I portion) is to study the side effects, drug breakdown (pharmacokinetics), and dosing of the drug MLN8237 when added to standard chemotherapy drugs, irinotecan and temozolomide. The goal of the second part of this clinical trial (Phase II portion) is to learn how many children and young adults show improvements in their neuroblastoma when treated with the combination of MLN8237, irinotecan, and temozolomide.

Official Title

Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Eligibility Criteria

Ages Eligible for Study: 12 Months to 30 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Contact us to find out if this trial is right for you.

Contact

Pediatric Hematology/Oncology
650-723-5535

View on ClinicalTrials.gov